Pill SplittingByR. Tim Webster, ScD. Author reply by Randall S. Stafford, MD, PhD,David C. Radley, BANovember 1st 2002
Do Disease Management Programs for Patients With Coronary Heart Disease Make a Difference? Experiences of Nine PracticesByMary N. Walsh, MD,Ross J. Simpson, Jr, MD,George J. Wan, PhD, MPH,Thomas W. Weiss, DrPH,Charles M. Alexander, MD,Leona E. Markson, ScDNovember 1st 2002
Use of a Disease Severity Index for Evaluation of Healthcare Costs and Management of Comorbidities of Patients With Diabetes MellitusByJames L. Rosenzweig, MD,Katie Weinger, EdD,Laurinda Poirier-Solomon, MPH,Mary Rushton, MBANovember 1st 2002
Understanding Changes in Primary Care Clinicians' Satisfaction From Depression Care Activities During Adoption of Selective Serotonin Reuptake InhibitorsByDiana Shye, PhD, MPH,Jonathan B. Brown, MPP, PhD,John P. Mullooly, PhD,Gregory A. Nichols, PhDNovember 1st 2002
State Regulation of Private Health Insurance: Prescription Drug Benefits, Experimental Treatments, and Consumer ProtectionByJane Nelson Bolin, PhD, JD, RN,Robert J. Buchanan, PhD,Scott R. Smith, PhDNovember 1st 2002
When Do Developing Countries Adopt Managed Care Policies and Technologies? Part I: Policies, Experience, and a Framework of PreconditionsByJohn W. Peabody, MD, PhD,Jeff Luck, MBA, PhDNovember 1st 2002
Therapeutic Options for the Management of Type 2 Diabetes MellitusByLiza Takiya, PharmD, CDE, BCPS,Sweta Chawla, PharmDNovember 1st 2002
